Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-angiogenesis
Lab / animal
OA: closed
CC0
⤵ 30 in-corpus citations
AI-generated summary
Lipoxin A4 treatment significantly inhibited endometriosis progression in mice by reducing lesion size, pro-inflammatory factors, MMP9 activity, and VEGF levels.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
PROBLEM: To evaluate the effects of the anti-inflammatory and anti-angiogenic roles of LXA4 on endometriosis in mice.
METHOD OF STUDY: Endometriosis was induced in 40 mice and separated into two groups. LXA4 group was administered by LXA4 for 3 weeks. The endometriotic lesions were counted, measured, and identified by pathology. The presence of a panel of pro-inflammatory factors was assessed by real-time RT-PCR, and enzyme-linked immunoassay, the mRNA, protein levels of matrix metalloproteinase (MMPs), and vascular endothelial growth factor (VEGF) were determined by real-time RT-PCR and immunohistochemistry; the activity of MMPs was evaluated by gelatin zymography.
RESULTS: Treatment with LXA4 significantly inhibited endometriotic lesion development (13.58 ± 4.01 mm(2) in LXA4 group and 23.20 ± 7.49 mm(2) , P = 0.0002), downregulated pro-inflammatory factors, suppressed the activity of MMP9, and reduced the VEGF levels associated with endometriosis in mice.
CONCLUSION: LXA4 may inhibit the progression of endometriosis possibly by anti-inflammation and anti-angiogenesis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (24)
- Angiogenic factors in endometriosis via openalex
- Concentrations of interferon-gamma-induced protein-10 (IP-10), an antiangiogenic substance, are decreased in peritoneal fluid of women with advanced endometriosis via openalex
- Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis via openalex
- Endometriosis and infertility: epidemiology and evidence-based treatments via openalex
- Expression of CD44s, vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritoneal, rectovaginal and ovarian endometriosis via openalex
- High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata via openalex
- Immunopathogenesis of pelvic endometriosis: role of hepatocyte growth factor, macrophages and ovarian steroids via openalex
- New insights into the pathophysiology of endometriosis: from chronic inflammation to danger signal via openalex
- Reactive oxygen species controls endometriosis progression via openalex
- Regulation of endometrial stromal cell matrix metalloproteinase activity and invasiveness by interleukin-8 via openalex
- Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines via openalex
- Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis via openalex
- Vascular endothelial growth factor A and C gene expression in endometriosis via openalex
- W2470199831 via openalex
- W1601517895 via openalex
- W1963996841 via openalex
- W1977609213 via openalex
- W2030776545 via openalex
- W2046387677 via openalex
- W2058218898 via openalex
- W2129806307 via openalex
- W2135423586 via openalex
- W2142438877 via openalex
- W1565755899 via openalex
Cited by (30)
- Chrysin-loaded PLGA nanoparticles alleviate the implantation of endometriotic lesions via attenuation of peritoneal inflammation and downregulating NF-κB activation-driven expression of angiogenic factors 2025
- D-chiro-inositol effectively counteracts endometriosis in a mouse model 2025
- In Vitro Anti Angiogenetic Activity of Traditional Plants Saraca asoca, Glycyrrhizia glabra and Curcuma longa Beneficial for Endometriosis Treatment 2024
- Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis 2023
- Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis 2022
- The Inflammatory Role of Pro-Resolving Mediators in Endometriosis: An Integrative Review 2021
- Immunosuppression and immunotherapy in endometriosis 2021
- Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies† 2021
- The Effect of Novel Medical Nonhormonal Treatments on the Angiogenesis of Endometriotic Lesions 2021
- Pentoxifylline for the treatment of endometriosis-associated pain and infertility 2021
- Lipoxin A4 inhibits the development of endometriosis in a mouse model by suppressing local estradiol synthesis 2020
- Sunitinib induces primary ectopic endometrial cell apoptosis through up-regulation of STAT1 in vitro 2020
- Analysis of key candidate genes and pathways of endometriosis pathophysiology by a genomics-bioinformatics approach 2019
- Use of immunomodulators to treat endometriosis 2019
- The link between immunity, autoimmunity and endometriosis: a literature update 2018
- Translational animal models for endometriosis research: a long and windy road 2018
- New developments in the medical treatment of endometriosis 2017
- Lipoxin A4 Suppresses Estrogen-Induced Epithelial-Mesenchymal Transition via ALXR-Dependent Manner in Endometriosis 2017
- An Update on Pathophysiology and Medical Management of Endometriosis 2016
- Proteome-Wide Effect of 17-β-Estradiol and Lipoxin A4 in an Endometriotic Epithelial Cell Line 2016
- Role of angiogenesis in endometriosis 2016
- Non-hormonal targets underlying endometriosis: A focus on molecular mechanisms 2015
- Experimental treatments of endometriosis 2015
- Lipoxin A4 regulates expression of the estrogen receptor and inhibits 17β-estradiol induced p38 mitogen-activated protein kinase phosphorylation in human endometriotic stromal cells 2014
- Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway 2014
- Peptide inhibitors of angiogenesis in endometriosis and the female reproductive system 2014
- Angiogenesis and endometriosis 2013
- The role of lipoxin A4 in endometrial biology and endometriosis 2013
- Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis In Montpellier, France 2013
- Anti-angiogenic treatment strategies for the therapy of endometriosis 2012
Source provenance
- europepmc
- last seen: 2026-10-16T06:09:50.462052+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:09:51.187616+00:00
- unpaywall
- last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0
· commercial use OK